Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide.

Autor: Böhmer GM, Drollmann A, Gleiter CH, Nave R, Böhmer, Gabriele M, Drollmann, Anton, Gleiter, Christoph H, Nave, Rüdiger

Publikováno v: Clinical Pharmacokinetics; 2008, Vol. 47 Issue 5, p343-349, 7p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effects of the Selective α5-GABAAR Antagonist S44819 on Excitability in the Human Brain: A TMS-EMG and TMS-EEG Phase I Study.

Autor: Darmani G; Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany., Zipser CM; Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany., Böhmer GM; Department of Clinical Pharmacology, University Hospital Tübingen, 72076 Tübingen, Germany., Deschet K; Institut de Recherches Internationales Servier (IRIS), 92284 Suresnes, France., Müller-Dahlhaus F; Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany., Belardinelli P; Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany., Schwab M; Department of Clinical Pharmacology, University Hospital Tübingen, 72076 Tübingen, Germany.; Department of Pharmacy and Biochemistry, University of Tübingen, 72076 Tübingen, Germany, and.; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany., Ziemann U; Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany, ulf.ziemann@uni-tuebingen.de.

Publikováno v: The Journal of neuroscience : the official journal of the Society for Neuroscience [J Neurosci] 2016 Dec 07; Vol. 36 (49), pp. 12312-12320.

No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.

Autor: Böhmer GM; Department of Clinical Pharmacology, University Hospital of Tübingen, Tübingen, Germany. gabriele.boehmer@med.uni-tuebingen.de, Gleiter CH, Mörike K, Nassr N, Walz A, Lahu G

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2011 Apr; Vol. 51 (4), pp. 594-602. Date of Electronic Publication: 2010 May 19.

The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.

Autor: Böhmer GM; Department of Clinical Pharmacology, University Hospital of Tübingen, Otfried-Müller-Str 45, D-72076 Tübingen, Germany. gabriele.boehmer@med.uni-tuebingen.de, Nassr N, Wenger M, Hünnemeyer A, Lahu G, Templin S, Gleiter CH, Hermann R

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2009 Apr; Vol. 49 (4), pp. 389-97.